Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Depakote/Depakote Sprinkle · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence Group I | EXPERIMENTAL | Depakote Delayed Release/Depakote Sprinkle |
| Sequence Group II | EXPERIMENTAL | Depakote ER |
| Name | Type | Description |
|---|---|---|
| Depakote Delayed-Release/Depakote Sprinkle | DRUG | Administered according to the subject's usual regimen. |
| Depakote ER | DRUG | Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle. |
Inclusion Criteria: * Male or female patient with a clinical diagnosis of epilepsy considered stable by the investigator. * Must be in good physical health, on the same dose of all medications, including Depakote and other AEDs, for 2 week period prior to randomization. * Minimum body weight of 37 ...
Depakote is used for pediatric epilepsy. It is a small molecule therapy developed by Abbott Laboratories for children and adolescents with epilepsy. A Phase 2 pediatric switch study evaluated the drug in patients aged 6 years and older in the United States.
Depakote is made by Abbott Laboratories, which trades under the ticker ABT. Abbott is the developer associated with the Depakote and Depakote Sprinkle products for pediatric epilepsy.
Depakote has been studied in Phase 2 clinical development for pediatric epilepsy. One Phase 2 trial has been completed, and no active trials are currently listed. The completed study enrolled 16 patients.
Depakote has been evaluated in the Phase 2 Pediatric Switch Study for Children and Adolescent Patients With Epilepsy, registered as NCT00646711. The trial was completed, enrolled 16 participants aged 6 years and older, and was conducted in the United States.
Depakote and Depakote Sprinkle are related product names for the same therapy. Depakote is also known as Depakote Delayed-Release or Depakote Sprinkle, reflecting different formulations of the same small molecule developed by Abbott Laboratories.